| scholarly article | Q13442814 |
| P2093 | author name string | Gerhard Wanner | |
| Wolfgang Hammerschmidt | |||
| Reinhard Zeidler | |||
| Romana Ruiss | |||
| Simon Jochum | |||
| Gilbert Reisbach | |||
| P2860 | cites work | The Protein Network of HIV Budding | Q24294993 |
| Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function | Q24530772 | ||
| Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis | Q24657081 | ||
| The ESCRT complexes: structure and mechanism of a membrane-trafficking network | Q24683234 | ||
| Epstein-Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis | Q24816875 | ||
| Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response | Q30442835 | ||
| Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines | Q33366499 | ||
| Clinical analysis and follow-up study of chronic active Epstein-Barr virus infection in 53 pediatric cases | Q33383411 | ||
| Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands | Q33603682 | ||
| Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients | Q33634455 | ||
| RNAs extracted from herpes simplex virus 1 virions: apparent selectivity of viral but not cellular RNAs packaged in virions. | Q33853688 | ||
| A listing of human tumor antigens recognized by T cells | Q33943569 | ||
| Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults | Q34004009 | ||
| Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults | Q34009363 | ||
| Memories that last forever: strategies for optimizing vaccine T-cell memory | Q34060493 | ||
| Cellular factors required for Lassa virus budding | Q34545961 | ||
| Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis | Q34565138 | ||
| Epstein-Barr virus-associated cancers: aetiology and treatment | Q35647396 | ||
| Immortalization of human B lymphocytes by a plasmid containing 71 kilobase pairs of Epstein-Barr virus DNA. | Q35829364 | ||
| Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells | Q36173276 | ||
| Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. | Q36228567 | ||
| A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates | Q36229606 | ||
| A first-generation packaging cell line for Epstein-Barr virus-derived vectors | Q36339632 | ||
| Large-scale production and concentration of infectious Epstein-Barr virus | Q36720732 | ||
| Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. | Q36766875 | ||
| Inhibition of Epstein-Barr virus (EBV) release from P3HR-1 and B95-8 cell lines by monoclonal antibodies to EBV membrane antigen gp350/220. | Q36877989 | ||
| Complement receptors CD21 and CD35 in humoral immunity | Q36938627 | ||
| Posttransplant lymphoproliferative disorder | Q36972819 | ||
| Requirement of B cells for generating CD4+ T cell memory | Q37135496 | ||
| Immune control of mammalian gamma-herpesviruses: lessons from murid herpesvirus-4. | Q37552360 | ||
| Proteins of purified Epstein-Barr virus | Q37621844 | ||
| Identification of a TAP-independent, immunoproteasome-dependent CD8+ T-cell epitope in Epstein-Barr virus latent membrane protein 2. | Q39700355 | ||
| Herpes simplex virus type 1 production requires a functional ESCRT-III complex but is independent of TSG101 and ALIX expression | Q39810759 | ||
| A phase I trial of epstein-barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation. | Q39935717 | ||
| Genetic design of an optimized packaging cell line for gene vectors transducing human B cells. | Q40327889 | ||
| Epstein-Barr virus vector-mediated gene transfer into human B cells: potential for antitumor vaccination | Q40379092 | ||
| Defective infectious particles and rare packaged genomes produced by cells carrying terminal-repeat-negative epstein-barr virus | Q40416450 | ||
| Epstein-Barr virus nuclear antigen 1 evades direct immune recognition by CD4+ T helper cells | Q40526255 | ||
| T cell priming in vivo: a major role for B cells in presenting antigen to T cells in lymph nodes | Q41355318 | ||
| Standardized and highly efficient expansion of Epstein-Barr virus-specific CD4+ T cells by using virus-like particles | Q42221268 | ||
| Human cytomegalovirus exploits ESCRT machinery in the process of virion maturation | Q42277859 | ||
| RNAs in the virion of Kaposi's sarcoma-associated herpesvirus. | Q42931216 | ||
| Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells | Q44013424 | ||
| B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells | Q44580466 | ||
| A global appraisal of immunodominant CD8 T cell responses to Epstein-Barr virus and cytomegalovirus by bulk screening | Q45740429 | ||
| The Epstein-Barr virus (EBV) major envelope glycoprotein gp350/220-specific antibody reactivities in the sera of patients with different EBV-associated diseases | Q45753602 | ||
| Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10. | Q45760353 | ||
| First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen | Q45785005 | ||
| Prolonged atypical illness associated with serological evidence of persistent Epstein-Barr virus infection | Q45806461 | ||
| Activation of B lymphocytes by Epstein-Barr virus/CR2 receptor interaction | Q45834675 | ||
| Identification and characterization of oriLyt, a lytic origin of DNA replication of Epstein-Barr virus | Q45840879 | ||
| Follicular and marginal zone B cells fail to cross-present MHC class I-restricted epitopes derived from viral particles | Q47884303 | ||
| Associations between infectious mononucleosis and cancer: record-linkage studies | Q59685272 | ||
| A subset of viral transcripts packaged within human cytomegalovirus particles | Q73943063 | ||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Epstein–Barr virus | Q6900 |
| P304 | page(s) | 13105-13113 | |
| P577 | publication date | 2011-10-12 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | A virus-like particle-based Epstein-Barr virus vaccine | |
| P478 | volume | 85 |
| Q38885776 | A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice |
| Q96128238 | A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection |
| Q27324235 | Adoptive transfer of EBV specific CD8+ T cell clones can transiently control EBV infection in humanized mice |
| Q39227077 | An Epstein-Barr virus mutant produces immunogenic defective particles devoid of viral DNA. |
| Q36294722 | Cell Walls and the Convergent Evolution of the Viral Envelope |
| Q92854437 | Cytomegalovirus and Epstein-Barr Virus Associations with Neurological Diseases and the Need for Vaccine Development |
| Q39170011 | Designing an effective vaccine to prevent Epstein-Barr virus-associated diseases: challenges and opportunities |
| Q38618258 | Different applications of virus-like particles in biology and medicine: Vaccination and delivery systems |
| Q93208514 | Differential effects of Belatacept on virus-specific memory versus de novo allo-specific T cell responses of kidney transplant recipients and healthy donors |
| Q41012612 | EBV-Associated Cancer and Autoimmunity: Searching for Therapies. |
| Q61796918 | Engineering extracellular vesicles as novel treatment options: exploiting herpesviral immunity in CLL |
| Q55032149 | Epstein-Barr Virus in Gliomas: Cause, Association, or Artifact? |
| Q58088134 | Epstein-Barr virus (EBV) status in colorectal cancer: a mini review |
| Q30838642 | Epstein-Barr virus particles induce centrosome amplification and chromosomal instability |
| Q35053650 | Epstein-barr virus vaccines |
| Q52599674 | Evaluating Human Immune Responses for Vaccine Development in a Novel Human Spleen Cell-Engrafted NOD-SCID-IL2rγNull Mouse Model. |
| Q45351171 | Expression, purification, and immunogenic characterization of Epstein-Barr virus recombinant EBNA1 protein in Pichia pastoris |
| Q37745980 | Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice |
| Q64104879 | Progress in EBV Vaccines |
| Q35991530 | RNAs in Epstein-Barr virions control early steps of infection |
| Q35060767 | Seroprevalence of cytomegalovirus, Epstein Barr virus and varicella zoster virus among pregnant women in Bradford: a cohort study |
| Q33812653 | Subviral particle as vaccine and vaccine platform |
| Q38248192 | Targeting Epstein-Barr virus infection as an intervention against multiple sclerosis. |
| Q38597261 | The Development of Prophylactic and Therapeutic EBV Vaccines |
| Q35815850 | The Epstein-Barr Virus Lytic Protein BZLF1 as a Candidate Target Antigen for Vaccine Development |
| Q34751018 | Tonsillitis and sore throat in children |
| Q59358941 | Vaccine Development for Epstein-Barr Virus |
| Q21089599 | Vaccines: from empirical development to rational design |
| Q45324534 | Virus like particles as a platform for cancer vaccine development. |
Search more.